Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

International Journal of Drug Policy

Volumn 19, Issue 1, 2008, Pages 71-78

  Munoz Plaza, Corrine E ^a   Strauss, Shiela ^a   Astone Twerell, Janetta ^a   Jarlais, Don Des ^b   Gwadz, Marya ^a   Hagan, Holly ^a   Osborne, Andrew ^a   Rosenblum, Andrew ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Drug treatment programmes; Hepatitis C; Medical treatment; Substance abuse

Indexed keywords

ANTIVIRUS AGENT; METHADONE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG USE; FEMALE; HEALTH PROGRAM; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; ATTITUDE; DATA COLLECTION; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; QUALITATIVE RESEARCH; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 38849099640     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.02.003     Document Type: Article

References (60)

1. Alter M.J., and Moyer L.A. The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology 18 Suppl. 1 (1998) S6-S10
2. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
3. Bae J.P. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Finance 18 (1997) 1-4
4. Best D., Noble A., Finch E., Gossop M., Sidwell C., and Strang J. Accuracy of perceptions of hepatitis B and C status: Cross sectional investigation of opiate addicts in treatment. British Medical Journal 319 (1999) 290-291
5. Brener L. Implicit and explicit attitudes of health care workers and their clients with hepatitis C: Is this related to treatment experiences?. Australian Hepatitis Chronicle 16 (2006) 24-26. http://www.hepatitisaustralia.com/PDFs/Chronicle16.pdf Retrieved 1st of December 2006 from http://www.hepatitisaustralia.com/PDFs/Chronicle16.pdf
6. Catz S.L., Kelly J.A., Bogart L.M., Benotsch E.G., and McAuliffe T.L. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology 19 2 (2000) 124-133
7. Centers for Disease Control & Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality World Report 47 RR-19 (1998) 1-39
8. Chitwood D.D., McBride D.C., French M.T., and Comerford M. Health care need and utilization: A preliminary comparison of injection drug users, other illicit drug users and nonusers. Substance Use and Misuse 34 4&5 (1999) 727-746
9. Chitwood D.D., Sanchez J., Comerford M., and McCoy C.B. Primary preventive health care among injection drug users, other sustained drug users, and non-users. Substance Use & Misuse 36 6/7 (2001) 807-824
10. Contoreggi C., Rexroad V.E., and Lange W.R. Current management of infectious complications in the injecting drug user. Journal of Substance Abuse Treatment 15 2 (1998) 95-106
11. Crofts N., Louie R., and Loff B. The next plague: Stigmatization and discrimination related to hepatitis C virus infection in Australia. Health & Human Rights 2 2 (1997) 87-97
12. Cullen W., Kelly Y., Stanley J., Langton D., and Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Irish Medical Journal 98 3 (2005) 73-74
13. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B., et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. European Addiction Research 8 (2002) 45-49
14. Davis M., and Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. International Journal of Drug Policy 15 (2004) 123-131
15. Day C., Ross J., and Dolan K. Hepatitis C-related discrimination among heroin users in Sydney: Drug user or hepatitis C discrimination?. Drug & Alcohol Review 22 3 (2003) 317-321
16. Dhopesh V.P., Taylor K.R., and Burke W.M. Survey of hepatitis B and C in addiction treatment unit. American Journal of Drug and Alcohol Abuse 26 4 (2000) 703-707
17. Doab A., Treloar C., and Dore G. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases 40 Suppl. 5 (2005) S313-S3120
18. Edlin B.R. Prevention and treatment of hepatitis C in injection drug users. Hepatology 36 5 (Suppl. 1) (2002) S210-S219
19. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. New England Journal of Medicine 345 (2001) 211-215
20. Evans M., Stotts A., Graham S., Schmitz J., and Grabowski J. Hepatitis C knowledge assessment and counseling within the context of substance abuse treatment. Addictive Disorders and Their Treatment 3 1 (2004) 18-26
21. Garfein R.S., Vlahov D., Galai N., Doherty M.C., and Nelson K.E. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 86 5 (1996) 655-661
22. Gifford S., O'Brien M., Smith A., Temple-Smith M., Stoove M., Mitchell D., et al. Australian men's experiences living with hepatitis C virus: Results from a cross-sectional survey. Journal of Gastroenterology Hepatology 20 1 (2005) 79-86
23. Golub E.T., Latka M., Hagan H., Havens J., Hudson S., Kapadia F., et al. Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the Beck's depression inventory. Journal of Urban Health 81 2 (2004) 278-290
24. Gordillo V., del Amo J., Soriano V., and Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 13 13 (1999) 1763-1769
25. Hagan H., Thiede H., Weiss H.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91 (2001) 42-46
26. Heimer R., Clair S., Grau L., Bluthenthal R., Marshall P., and Singer M. Hepatitis-associated knowledge is low and the risks are high among HIV-aware injection drug users in three US cities. Addiction 97 (2002) 1277-1287
27. Hopwood M., and Treloar C. The experience of Interferon-based treatments for hepatitis C infection. Qualitative Health Research 15 5 (2005) 635-646
28. Hopwood M., Treloar C., and Bryant J. Hepatitis C and injecting-related discrimination in New South Wales, Australia. Drugs: Education, Prevention and Policy 13 1 (2006) 61-75
29. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 7 9 (2002) 942-947
30. Koch M., and Banys P. Liver transplantation and opioid dependence. Journal of the American Medical Association 285 (2001) 1056-1058
31. Kremer H., Ironson G., Schneiderman N., and Hautzinger M. To take or not to take: Decision-making about antiretroviral treatment in people living with HIV/AIDS. Aids Patient Care and STDs 20 5 (2006) 335-349
32. Kwiatkowski C.F., Fortuin E., Corsi K., and Booth R.E. The association between knowledge of hepatitis C virus status and risk behaviours in injection drug users. Addiction 97 (2002) 1289-1294
33. McNally, S., Temple-Smith, M., Pitts, M. (2004). Making decisions about hepatitis C treatment. Australian Research Centre in Sex, Health and Society (pp. 1-92), La Trobe University Monograph Series Number 49.
34. Milby J.B., Sims M.K., Khuder S., Schumacher J.E., Huggins N., McLellan A.T., et al. Psychiatric comorbidity: Prevalence in methadone maintenance treatment. American Journal of Drug & Alcohol Abuse 22 (1996) 95-107
35. Morrill J., Shrestha M., and Grant R. Barriers to the treatment of hepatitis C: Patient, provider and system factors. Journal of General Internal Medicine 20 8 (2005) 754-758
36. National Institutes of Health. Management of hepatitis C: 1997. NIH Consensus and State-of-the-Science Statements 15 3 (1997) 1-49. http://consensus.nih.gov/1997/1997HepatitisC105html.htm Retrieved 15th of July 2006 from http://consensus.nih.gov/1997/1997HepatitisC105html.htm
37. National Institutes of Health. Management of hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 19 3 (2002) 1-46. http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm Retrieved 15th of July 2006 from http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
38. National Institutes of Health (2003). Chronic Hepatitis C: Current Disease Management. NIH Publication No. 03-4230. Retrieved 5th of July 2006 from http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/.
39. Osher F.C., Goldberg R.W., McNary S.W., Swartz M.S., Essock S.M., Butterfield M.I., et al. Substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatric Services 54 6 (2003) 842-847
40. Pearlman B. Hepatitis C infection: A clinical review. Southern Medical Journal 97 4 (2004) 365-373
41. Pearlman B. Hepatitis C treatment update. American Journal of Medicine 117 5 (2004) 344-352
42. Rhodes T., Davis M., and Judd A. Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction 99 (2004) 621-633
43. Schaefer M., Heinz A., and Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules?. Addiction 99 9 (2004) 1167-1175
44. Schering-Plough, (2006). Patient Assistance and Support Program. Retrieved 6th of December from http://www.schering-plough.com/schering_plough/pc/patient_programs.jsp.
45. Schiffman M.L. Side effects of medical therapy for chronic hepatitis C. Annals of Hepatology 3 1 (2004) 5-10
46. Scientific Software Development GmbH: Copyright (1991-2006).
47. Stein M., Maksad J., and Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence 61 (2001) 211-215
48. Stephenson J. Former addicts face barriers to treatment for HCV. Journal of the American Medical Association 285 8 (2001) 1003-1005
49. Stoove M., Gifford S., and Dore G. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug & Alcohol Dependence 77 1 (2005) 81-86
50. Swan, T. (2004). Blockbusters beckon: Proliferation of polymerase inhibitors and other tales from the HCV crypt. The Body-The Complete HIV/AIDS Resource. Retrieved on 20th of July 2006 from http://www.thebody.com/tag/feb04/hcv.html.
51. Sylvestre D.L. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug and Alcohol Dependence 67 (2002) 117-123
52. Sylvestre, D. L. (2003). Managing those important unimportant side effects. Medical Writers Circle-HCV Advocate. Retrieved 6th of December from http://www.hcvadvocate.org/hcsp/articles/Sylvestre-2.html.
53. Sylvestre D.L., Loftis J.M., Hauser P., Genser S., Cesari H., Borek N., et al. Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care. Journal of Urban Health 81 4 (2004) 719-734
54. Teo M., and Hayes P. Management of hepatitis C. British Medical Journal 70 (2004) 51-69
55. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 4 (1995) 212-220
56. Treloar C.J., Hopwood M.N., and Loveday S.K. Hepatitis C-related discrimination in healthcare. Report of the Third Australasian Conference on Hepatitis C, Melbourne, March 2002. Medical Journal of Australia 177 5 (1996) 233-234
57. Walley A.Y., White M., Song Y., Kushell M., and Tulsky J.P. Women methadone patients are less knowledgeable about hepatitis C treatment. Poster presented at the sixty-fifth annual scientific meeting of the College on Problems of Drug Dependence (2003)
58. Ward R.P., Kugelmas M., and Libsch K.D. Management of hepatitis C: Evaluating suitability for drug therapy. American Family Physician 69 6 (2004) 1429-1436
59. Zeuzem S. Treatment of hepatitis C virus infection. Schweiz Rundsch Med Prax 94 18 (2005) 721-726
60. Zickmund S., Hillis S.L., Barnett M.J., Ippolito L., and LaBrecque D.R. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 39 (2004) 999-1007